Suchergebnisse - "Comment"

PubPharm (367)

1

Overcoming Resistance in Chronic Lymphocytic Leukemia-Maybe Less Is More?

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2024

von Al-Sawaf, O. | Davids, M.

CommentOn: Clin Cancer Res. 2024 Feb 1;30(3):498-505. - PMID 37955424

2

Case report : Clinical complete response in advanced ALK-positive lung squamous cell carcinoma: a case study of successful anti-PD-1 immunotherapy post ALK-TKIs failure

enthalten in: Frontiers in immunology | 2024

von Yang, C. | Zeng, R. | Zha, Y. | +5

CommentOn: Zhongguo Fei Ai Za Zhi. 2022 Sep 20;25(9):696-700. - PMID 36172736

3

Letter to the Editor : SMAC mimetics inhibit human T cell proliferation and fail to augment type 1 cytokine responses

enthalten in: Cellular immunology | 2024

von Bourhis, J. | Sun, X. | Tao, Y.

CommentOn: Cell Immunol. 2023 Feb;384:104674. - PMID 36706656

4

Comment on : Brentuximab vedotin-related neuropathy in a patient with Gilbert syndrome: Do mutations of UGT1A1 gene affect brentuximab toxicity?

enthalten in: Pediatric blood & cancer | 2023

von Marco, C. | Padró-Miquel, A. | Domingo-Domenech, E. | +1

CommentOn: Pediatr Blood Cancer. 2022 Jun;69(6):e29444. - PMID 34767681

5

Fine-tuning chemical genetics to identify physiologic drug targets

enthalten in: Cell chemical biology | 2023

von Vostal, L. | Kapoor, T.

CommentOn: Cell Chem Biol. 2023 Nov 16;30(11):1453-1467.e8. - PMID 37607550

6

Unleashing dendritic cell-mediated tumor clearance by targeting Bcl-2

enthalten in: Trends in immunology | 2023

von Martin, S.

CommentOn: Cancer Discov. 2023 Nov 1;13(11):2448-2469. - PMID 37623817

7

Oncolytic virus and inhibitor for NEDD8-activating enzyme pevonedistat : Promising combination for cancer therapy?

enthalten in: Molecular therapy : the journal of the American Society of Gene Therapy | 2023

von Guo, Z.

CommentOn: Mol Ther. 2023 Nov 1;31(11):3176-3192. - PMID 37766429

8

Distinct Mechanisms of Resistance to CDK4/6 Inhibitors Require Specific Subsequent Treatment Strategies : One Size Does Not Fit All

enthalten in: Cancer research | 2023

von Wingate, H. | Keyomarsi, K.

CommentOn: Cancer Res. 2023 Oct 2;83(19):3264-3283. - PMID 37384539

9

Outcomes with molecularly targeted agents as salvage therapy following frontline venetoclax + hypomethylating agent in adults with acute myeloid leukemia : A multicenter retrospective analysis

enthalten in: Leukemia research | 2023

von Khanna, V. | Azenkot, T. | Liu, S. | +8

CommentOn: Leuk Res. 2022 Nov;122:106942. - PMID 36108424

10

Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO) : A Phase II Trial

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2023

von Morgan, R. | Clamp, A. | White, D. | +25

CommentOn: Clin Cancer Res. 2023 Jul 14;29(14):2563-2566. - PMID 37191665

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[37]